Literature DB >> 6125207

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

M S Lennard, J H Silas, S Freestone, J Trevethick.   

Abstract

Eight healthy volunteers received oral metoprolol 200 mg once daily for a week. The AUC, half-life and duration of beta-adrenoceptor blockade on day 7 was much greater in two subjects than in the remaining six. This suggested that the metabolism of metoprolol was impaired in two and the effect was therefore prolonged. Subsequent testing of oxidation phenotype with oral debrisoquine showed that the subjects with high metoprolol availability were also poor hydroxylators of debrisoquine. The urinary debrisoquine/4-hydroxydebrisoquine ratio was highly correlated with metoprolol AUC, half-life and beta-adrenoceptor blockade at 24 h. Thus patients with a genetic defect in drug oxidation, when treated with metoprolol, are likely to have high plasma concentrations and a prolonged effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125207      PMCID: PMC1427748          DOI: 10.1111/j.1365-2125.1982.tb01982.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension.

Authors:  C von Bahr; P Collste; M Frisk-Holmberg; K Haglund; L Jorfelt; M Orme; J Ostman; F Sjoqvist
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

Review 4.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

5.  Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].

Authors:  J R Idle; T P Sloan; R L Smith; L A Wakile
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

6.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

7.  Why hypertensive patients vary in their response to oral debrisoquine.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br Med J       Date:  1977-02-12

8.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

9.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  43 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].

Authors:  A Seeringer; J Kirchheiner
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

4.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  CNS-related side-effects with metoprolol and atenolol.

Authors:  J R Cove-Smith; C A Kirk
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors:  E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

7.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

10.  Sparteine oxidation polymorphism: a family study.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.